Targets › IGHG1
2 programs from 2 companies in 4 trials: 3 Phase 2, 1 Phase 3; Other, Genitourinary; next expected readout Feb 2027.
Constant region of immunoglobulin (Ig) heavy chains. Igs are membrane-bound or secreted glycoproteins produced by B lymphocytes. (UniProt, P01857)
Open in Phaseline: the race on IGHG1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Hansa Biopharma | Imlifidase IgG-degrading enzyme that cleaves IgG into F(ab')2 and Fc fragments, neutralizing Fc-media | IGHG1 | Phase 3 | Long Term Efficacy and Safety; Kidney Transplantation in Highly Sensitized Patients | Feb 2027 |
| International Peace Maternity and Child Health Hospital | intravenous immunoglobulin (IVIG) Intravenous immunoglobulin providing pooled human IgG antibodies for immunomodulation and | IGHG1 | Phase 2 | Bronchopulmonary Dysplasia | Sep 2027 |
Bronchopulmonary Dysplasia (2) Long Term Efficacy and Safety (1) Kidney Transplantation in Highly Sensitized Patients (1)
protein or peptide (2)
Hansa Biopharma (1) International Peace Maternity and Child Health Hospital (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.